BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aβ upstream of where most others have focused - the lead programs are in ophthalmology

Executive Chairman Alexander Gebauer describes this approach to aiming to prevent toxic amyloid beta clumps from developing in the first place, and why Galimedix has focused on conditions like dry AMD and glaucoma a little ahead of its Alzheimer's program.

Brought to you by